Literature DB >> 22156971

Less decrease in risk behaviour from pre-HIV to post-HIV seroconversion among MSM in the combination antiretroviral therapy era compared with the pre-combination antiretroviral therapy era.

Titia Heijman1, Ronald B Geskus, Udi Davidovich, Roel A Coutinho, Maria Prins, Ineke G Stolte.   

Abstract

OBJECTIVE: To gain insight in the ongoing HIV transmission, we compared sexual risk behaviour pre-HIV and post-HIV seroconversion in 206 MSM participating in the Amsterdam Cohort Studies (1984-2008) before and after the introduction of combination antiretroviral therapy (cART). DESIGN AND METHODS: MSM completed behavioural questionnaires and were tested for HIV antibodies every 6 months. Trends in anal intercourse and number of sex partners from 4 years before HIV seroconversion until 4 years after diagnosis were analysed with latent class random effects logistic regression models.
RESULTS: The risk of having unprotected anal intercourse (UAI) 1 year after HIV diagnosis decreased significantly when compared with 1 year before diagnosis in both the pre-cART era [difference, 30%; 95% confidence interval (CI), 22-36%] and cART era (difference, 19%; 95% CI, 9-30%). In contrast to a continuing decrease of UAI in the pre-cART era, the probability of UAI in the cART era increased again to preseroconversion levels (61%; 95% CI, 48-74%)) 4 years after diagnosis.
CONCLUSION: This study provides evidence that recently seroconverted MSM reduce their sexual risk behaviour following HIV diagnosis both in the pre-cART as well as the cART period. However, in the cART period this reduction in sexual risk behaviour is less and returns to pre-cART levels within 4 years. These findings not only confirm the need for early HIV testing but also make it clear that much more effort should go into identifying, counselling, and possibly treating recently seroconverted MSM who have been found to be one of the most important drivers of HIV transmission among MSM.

Mesh:

Substances:

Year:  2012        PMID: 22156971     DOI: 10.1097/QAD.0b013e32834f9d7c

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  24 in total

1.  Examining the role of serostatus disclosure on unprotected sex among people living with HIV.

Authors:  Sarahmona Przybyla; Carol Golin; Laura Widman; Catherine Grodensky; Jo Anne Earp; Chirayath Suchindran
Journal:  AIDS Patient Care STDS       Date:  2014-12       Impact factor: 5.078

2.  Cost savings associated with testing of antibodies, antigens, and nucleic acids for diagnosis of acute HIV infection.

Authors:  Maile Y Karris; Christy M Anderson; Sheldon R Morris; Davey M Smith; Susan J Little
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

3.  Behavioral changes following HIV seroconversion during the historical expansion of HIV treatment in the United States.

Authors:  Wenjia Zhu; Samuel A Bazzi; Angela R Bazzi
Journal:  AIDS       Date:  2019-01-27       Impact factor: 4.177

4.  Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Authors:  A J Rodger; F C Lampe; A E Grulich; M Fisher; G Friedland; N Phanuphak; J R Bogner; L C Pereira; C Rietmeijer; W Burman; A N Phillips
Journal:  HIV Med       Date:  2015-04       Impact factor: 3.180

5.  Positive choices: outcomes of a brief risk reduction intervention for newly HIV-diagnosed men who have sex with men.

Authors:  Kathleen J Sikkema; Laurie Abler; Nathan B Hansen; Patrick A Wilson; Anya S Drabkin; Arlene Kochman; Jessica C MacFarlane; Allyson DeLorenzo; Gal Mayer; Melissa H Watt; William Nazareth
Journal:  AIDS Behav       Date:  2014-09

Review 6.  Global challenges in human immunodeficiency virus and syphilis coinfection among men who have sex with men.

Authors:  Chelsea P Roberts; Jeffrey D Klausner
Journal:  Expert Rev Anti Infect Ther       Date:  2016-09-23       Impact factor: 5.091

7.  Highly active antiretroviral therapy is associated with decreased incidence of sexually transmitted diseases in a Taiwanese HIV-positive population.

Authors:  Shu-Hsing Cheng; Chin-Hui Yang; Yu-Mei Hsueh
Journal:  AIDS Patient Care STDS       Date:  2013-02-26       Impact factor: 5.078

8.  Risk patterns preceding diagnosis among newly HIV-diagnosed men who have sex with men in New York City.

Authors:  Anya S Drabkin; Kathleen J Sikkema; Patrick A Wilson; Christina S Meade; Nathan B Hansen; Allyson DeLorenzo; Arlene Kochman; Jessica C MacFarlane; Melissa H Watt; Frances M Aunon; Krista W Ranby; Gal Mayer
Journal:  AIDS Patient Care STDS       Date:  2013-06       Impact factor: 5.078

9.  Changes in sexual risk behavior among MSM participating in a research cohort in coastal Kenya.

Authors:  Lisanne M Möller; Ineke G Stolte; Ronald B Geskus; Haile Selassie Okuku; Elizabeth Wahome; Matt A Price; Maria Prins; Susan M Graham; Eduard J Sanders
Journal:  AIDS       Date:  2015-12       Impact factor: 4.177

10.  The impact of age, HIV serostatus and seroconversion on methamphetamine use.

Authors:  Jessica L Montoya; Jordan Cattie; Erin Morgan; Steven Paul Woods; Mariana Cherner; David J Moore; J Hampton Atkinson; Igor Grant
Journal:  Am J Drug Alcohol Abuse       Date:  2016-02-02       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.